Research programme: immune modulation therapy - Psionix
Latest Information Update: 20 Apr 2007
At a glance
- Originator Psionix
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Immunological disorders
Most Recent Events
- 07 Oct 2003 Preclinical trials in Immunological disorders in United Kingdom (unspecified route)